Floatz logo

Xeomin®

Spasticity as Sequela of Stroke

Campus Bio-Medico UniversityActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Spasticity as Sequela of Stroke cohort.

Asset / SponsorPhaseRating
DWP-450
Seoul National University Hospital
Phase 4BB
AE-MARJORAM
Hong Kong Metropolitan University
N/AD

Same molecule, other indications

Xeomin® is also rated in:

Muscle SpasticityDormant
BBB
Indicative ·
79 / 100
View asset →
Migraine DisordersDormant
BBB
Indicative ·
77 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →